The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, phase II, multicenter, double-blind, placebo-controlled study evaluating onartuzumab (MetMAb) in combination with mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
Johanna C. Bendell
No relevant relationships to disclose
Thomas J. Ervin
No relevant relationships to disclose
David H. Gallinson
No relevant relationships to disclose
Jaswinder Singh
No relevant relationships to disclose
James Alfred Wallace
No relevant relationships to disclose
Mansoor N. Saleh
No relevant relationships to disclose
Marcy Vallone
Employment or Leadership Position - Sarah Cannon Research Institute
Stephen Paul Hack
Employment or Leadership Position - Genentech